Molecular Drivers of Chemoradiation Resistance in Cervical Cancer

Category

Hyderabad, India March 2026: Researchers have identified key genomic and proteomic alterations linked to resistance to chemoradiotherapy in cervical cancer, offering new insights that could help guide personalized treatment strategies for patients in India.

Cervical cancer remains one of the most common cancers among women in India (Only second after breast cancer), with many cases diagnosed at advanced stages. Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced disease, yet 30–40% of patients experience treatment failure, highlighting the need to better understand the biological mechanisms behind resistance.

In a new study titled “Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer,” researchers conducted a comprehensive analysis combining whole-genome sequencing (WGS), Whole exome sequencing (WES) and high-resolution mass spectrometry-based proteomics from thirty six tumor tissues and matched blood samples to investigate molecular differences between patients who respond to treatment and those who do not.

The study represents the first proteogenomic investigation and the first WGS-based analysis of chemoradiation resistance in cervical cancer from the Indian population. Dr. Shrikanth Manda, AVP of DrSeq Lab at Nucleome Informatics, co-authored the study and collaborated with the research team to analyze the genomic and proteomic datasets.

Key genomic findings

The researchers identified recurrent mutations in PIK3CA and KMT2D, two genes frequently implicated in cancer development. Mutation signature analysis also revealed a strong presence of APOBEC-associated mutagenesis, a DNA editing process known to contribute to tumor evolution.

Notably, the study discovered EGFR amplification and STK11 deletion exclusively in tumors from patients who were resistant to chemoradiotherapy, suggesting that these alterations may play a role in treatment failure.

Proteomic insights

Using proteomic profiling, the researchers identified 73 significantly dysregulated proteins associated with resistance. Among the most strongly upregulated proteins were STX3, SERPINB7, LBP, EMILIN2, and NQO2. STX3 was validated in an external cohort as well using IHC.

Further integrative pathway analysis revealed that DNA repair pathways were highly active in chemoradiation-resistant tumors, indicating that enhanced DNA repair capacity may enable cancer cells to survive radiation-induced damage.

Potential biomarkers and therapeutic targets

The study highlights STK11 and STX3 as potential predictive biomarkers for poor response to chemoradiotherapy. In addition, EGFR amplification observed in resistant tumors suggests that EGFR-targeted therapies could represent a promising treatment strategy for this subgroup of patients.

The findings demonstrate how multi-omics approaches integrating genomic and proteomic data can uncover clinically relevant biomarkers and therapeutic targets, potentially paving the way for more precise and personalized treatment strategies in cervical cancer.

The full study is available at:
https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.70108